Stock Price & Analysis

The S1 support level for PRME Stock is $2.38 ,The R1 resistant level for PRME Stock is $3.23.

As of the end of day on 2025-02-25, the price of PRME Stock was $2.64.

The target price for PRME Stock according to analyst rating is 14.50, with the highest price target at 19.00 and the lowest at 10.00. Analysts have a Moderate Buy rating on PRME Stock overall.

The market cap of PRME is $346.3M.

Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. The Company is leveraging its prime editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted deoxyribonucleic acid (DNA) modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Its Prime Editors have two main components that act together to edit DNA: a Prime Editor protein, having a Cas protein and a reverse transcriptase enzyme that may be fused together, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It is progressing a diversified portfolio of about 18 programs initially focused on genetic diseases.

PRME has a total of 234 employees.